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INTRODUCTION
Inosine 5’-monophosphate dehydrogenase (IMPDH)
catalyzes the committed step in de novo guanine
nucleotide biosynthesis (1,2). Fast-growing cells are in
high demand for guanine nucleotides, which is why
IMPDH activity is increased in viral infections, tumors,
and rapidly proliferating tissues (3,4). In various cell lines,
IMPDH inhibitors induce apoptosis and differentiation
(5,6) and are used in antiviral and immunosuppressive
chemotherapy (4).
Tiazofurin (2-β-D-ribofurasylthiazole-4-carboxamide,
TR) selectively inhibits the activity of IMPDH (7,8). The
inhibition of IMPDH induced by TR is due to its active
metabolite, thiazol-4-carboxamide adenine dinucleotide
(TAD), an analog of nicotine-amid adenine dinucleotide
(NAD+). TAD binds tightly to the NADH site, thus
inhibiting the activity of IMPDH (9,10). Though similar
to that of NADH, the inhibitory effect of TAD is three
orders of magnitude higher than the one of natural NADH
(10). Since IMPDH is increased in malignant and
leukemia cells (7,8), potent IMPDH inhibitory properties
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ABSTRACT
Objective. Inosine 5’-monophosphate dehydrogenase
(IMPDH) activity in cancer cells is increased. Tiazofurin
selectively inhibits the activity of IMPDH, and it has been
granted for the treatment of different cancers and new viral
diseases. Its widespread use was limited because exposure to
tiazofurin under certain circumstances was found to have a
higher frequency of severe non-hematologic toxicity.
Therefore, the objective of this study was to examine
genotoxic action and inducement of DNA damage of
tiazofurin using the comet assay.
Methods. The ability of tiazofurin to induce DNA damage
was evaluated using single-cell gel electrophoresis (SCGE)
technique/comet assay. Human whole blood cells were
exposed to three final concentrations of tiazofurin (1 µM/mL,
2 µM/mL, and 5 µM/mL) for 30 min in vitro.
Results. Our results indicate that tiazofurin produced a
significant level of DNA damage on whole blood cells after
30 min of exposure vs. control. All tested concentrations were
significantly comet-forming, in a concentration-dependent
manner.
Conclusion. Our investigation on the tiazofurin-treated
cells and their relationship to the formation of DNA damage
demonstrated that the genotoxic effect was induced after
exposure to tiazofurin under described conditions.
Key words: DNA damage; mutagenicity tests; comet
assay
SAŽETAK
Cilj. Aktivnost inozin 5’-monofosfat dehidrogenaze
(IMPDH) povećana je u ćelijama karcinoma. Tiazofurin
selektivno inhibira aktivnost IMPDH i odobren je za lečenje
različitih karcinoma i novih virusnih bolesti. Njegova široko
rasprostranjena upotreba bila je ograničena jer je utvrđeno
da je izloženost tiazofurinu pod određenim okolnostima
imala veću incidencu ozbiljne nehematološke toksičnosti.
Stoga je cilj ove studije bio da se pomoću komet testa ispita
genotoksično delovanje i izazivanje DNK oštećenja
tiazofurinom.
Metode. Sposobnost tiazofurina da izazove DNK
oštećenje procenjena je primenom elektroforeze DNK
pojedinačnih ćelija (SCGE) / komet testa. Ćelije pune krvi su
bile izložene trima konačnim koncentracijama tiazofurina (1
µM/mL, 2  µM/mL, and 5  µM/mL) tokom 30 minuta in vitro.
Rezultati. Naši rezultati ukazuju na to da je tiazofurin
proizveo značajan nivo DNK oštećenja na ćelijama pune krvi
nakon 30 minuta izlaganja u odnosu na kontrolu. Sve
ispitivane koncentracije su dovele do značajnog nastanka
kometa, pri čemu je nivo oštećenja rastao s koncentracijom.
Zaključak. Naše istraživanje ćelija tretiranih
tiazofurinom i njihova reakcija na izazivanje DNK oštećenja
pokazalo je da je tiazofurin ispoljio genotoksični efekat pod
opisanim uslovima.
Ključne reči: DNK oštećenje; testovi mutagenosti; komet
test
and antitumor activity (11,12) lead to the examination of
TR and its derivates for use in the treatment of cancer (13-
15). TR-induced apoptosis in K562 and HL-60 myeloid
cells, as well as in Jurkat and MOLT-4 T lymphoid cell
lines (16,17). TR induced complete hematological
remissions in patients with end-stage acute non-
lymphocytic leukemia or myeloblastic crises of chronic
myeloid leukemia (18). TR was granted orphan drug status
for the treatment of chronic myelogenous leukemia,
though widespread use was limited due to its toxicity (4,
9,19). Non-hematologic toxicity of TR included serum
transaminase elevations, headache, and signs of central
nervous system, cardiac and ocular toxicity (20). Studies
revealed that TR induced an increase in the frequency of
micronuclei (MNi) in peripheral blood lymphocytes,
correlated to the time of exposition (21). An investigation
of the genotoxic effects of TR stereoisomers showed them
as far less genotoxic than TR (22). Therefore, the current
study aimed to examine genotoxic action and assess the
level of DNA damage in human whole blood cells (WBC)
caused by tiazofurin through in vitro single cell gel
electrophoresis technique (comet assay).
mATeRIAl AND meThODs
2.1. Subjects
Peripheral blood samples were collected in
heparinized containers from three healthy donors aged
between 21 and 55. Donors did not receive any therapy or
medications, take any dietary supplements, consume
alcohol, or smoke during the study.
2.2. Study Design
Tiazofurin (CAS no. 60084-10-8, Biosynth, Staad,
Switzerland) was used in this study, diluted in phosphate-
buffered saline (PBS, Torlak Institute of Immunology and
Virology, Belgrade, Serbia) to final concentrations of 1
µM/mL, 2 µM/mL, and 5 µM/mL. Three final
concentrations of tiazofurin were determined according to
the literature data (21, 23-25). To evaluate the genotoxic
potential of tiazofurin in human peripheral blood samples,
they were incubated for 30 minutes at 37°C with chosen
concentrations of tiazofurin. Hydrogen peroxide (H2O2,
CAS no. 7722-84-1, ZORKA Pharma, Sabac, Serbia), a
well-known oxidant, was used as a positive control. 50 µM
H2O2 was added to the cells for 20 min at 4°C. Negative
controls were treated with PBS at 37°C for 30 min. The
experiments for all three samples were performed in
duplicate.
2.3. The Single Cell Gel Electrophoresis Assay
The lysis, denaturation, electrophoresis, and staining in
the alkaline comet assay were performed as described by
Singh et al. (26). The whole blood samples (6 μL per slide)
were suspended in 0.67% low-melting-point (LMP)
agarose (Sigma-Aldrich, St. Louis, MO) and pipetted onto
previously coated microscope slides. After solidifying at
4°C for 5 min and the removal of the coverslips, the cell
suspensions were treated as described above. Following
the treatments, the slides were covered with a layer of
0.5% LMP agarose and left to solidify at 4°C for 5 min.
Afterwards, the slides were placed in a pre-chilled lysing
solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 1%
Triton X100, and 10% dimethylsulfoxide, adjusted with
NaOH to pH 10) and left to stay overnight at 4°C. After
the unwinding and electrophoresis (in electrophoresis
buffer at pH 13 - 10 M NaOH, 200 mM EDTA) the next
day, the slides were rinsed - two times for 10 min in
neutralization buffer (0.4 M Tris, pH 7.5) and one time in
distilled water. Staining was done with ethidium bromide
(20 μg/L, Sigma-Aldrich, St. Louis, MO). The comets
were analyzed at a magnification of 100x, on an Olympus
BX 50 microscope (Olympus Optical Co., GmbH,
Hamburg, Germany), equipped with a mercury lamp HBO
(50 W, 516–560 nm, Carl Zeiss Inc.), connected to a
computer via CCD camera, allowing appropriate zoom
(Figure 1). The comets were visually scored and,
depending on the extent of DNA migration, classified into
five categories according to Anderson et al. (27): A - no
damage; B - low-level damage; C - medium level damage;
D - high-level damage; and E - total damage. 50 randomly
selected comets were scored on each of 2 slides per subject
(100 in total per subject). DNA damage was characterized
as DNA migration over 5% (B+C+D+E comet categories)
for all three subjects.
2.4. Statistical Analysis
The results were obtained as the mean and standard
error (SEM), for n=3. Data were processed in the
GraphPad Prism 6.0 software, using analysis of variance
(one-way ANOVA) and Tukey’s posthoc test for
determination of statistical significance. A difference at
p<0.05 was considered statistically significant.
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Figure 1. The example of tiazofurin-exposed cells,
showing DNA migration after treatment
ResUlTs
Figure 2 summarizes the effect of TR in WBC (mean
of three experiments from different donors). Comet assay
analysis revealed that the tested range of concentrations (1
μM/mL, 2 μM/mL, and 5 μM/mL) induced a significant
level of DNA damage when compared to untreated cells
(incubation with PBS). TR induced a concentration-
related increase in DNA migration. Moreover, the effect of
5 μM/mL TR showed a statistically significantly greater
level of DNA damage than 1 μM/mL TR. Table 1
represents the effect of TR expressed by the percentage of
comet categories among affected WBC. Low and medium
levels of DNA migration (B and C comet categories) are
mostly present in cells treated with tested concentrations
of TR, as well as in the ones treated with controls. Figure
3 shows the effect of TR on WBC of individual donors,
considering a wide age range between them. The same
trend is visible as in Table 1.
DIsCUssION
In vitro and in vivo studies found that TR has an
antiproliferative effect on tumor cells (12,28). TR was also
tested in Lewis lung carcinoma and MM-96 human
melanoma cells, where resistance to tiazofurin was
quickly developed (25). Despite the fact that a good
correlation was detected between biochemical parameters
and clinical response in leukemic patients, especially the
ones with chronic myeloid leukemia, phase I trials were
discontinued because of toxicity (3). An analysis of the
patient database showed that exposure to TR under certain
circumstances may result in a higher frequency of severe
non-hematologic toxicity (20).
Our results indicate that TR induces DNA damage in
WBC after an in vitro exposure period of 30 min. A
significant increase in DNA damage is detected by the
comet assay after treatment with 1 μM/mL, 2 μM/mL, and
5 μM/mL TR in comparison to incubation with PBS.
Another test suitable to monitor genotoxicity in cells, the
micronucleus test (MN), demonstrated that the
proliferation potential of cells was significantly reduced,
especially after a prolonged treatment with TR (21).
Nevertheless, the same study revealed that the clastogenic
properties of TR were evidenced in the treatment period of
17 h (21). A study by Berger et al. (23) showed that
continuous exposure of cells to tiazofurin for 24 h and 48
h resulted in a dose-dependent increase in DNA strand
breaks, measured by alkaline elution. TR-induced strand
breaks appeared more resistant to repair than those
induced by 75-150 rad of γ-irradiation. Results obtained in
our study reveal that even short-term exposure to TR can
cause damage of hereditary material, unlike the ones
obtained by the MN test. On the other hand, not only that
our data are consistent with the study which showed dose-
dependent increases in DNA damage induced by TR, but
they show that the highest tested concentration (5 μM/mL)
induced a statistically significant increase compared to the
lowest concentration (1 μM/mL).
Besides its ability to act as a DNA strand-disrupting
substance, some studies indicated that TR may be useful in
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Figure 2. Genotoxic effect of TR in tested concentrations
(1 μM/mL, 2 μM/mL, and 5 μM/mL) after 30 min of
treatment at 37°C, positive control with H2O2, and
negative control with PBS. Bars represent mean number
of cells with DNA damage ± SEM, for n = 3. ***p <
0.0001 vs. PBS; *p < 0.05, 1 μM/mL vs. 5 μM/mL
Table 1. Relationship between the effect of TR and the
degree of DNA damage. The values represent the
percentage of comet categories among affected WBC: B
- low-level damage, C - medium level damage, D - high-
level damage, and E - total damage
Figure 3. Relationship between the effect of TR and the
degree of DNA damage, represented as values for
individual donors (1-22 years, 2-21 years, 3-55 years).
Values are expressed as the percentage of comet
categories among affected WBC: B - low-level damage,
C - medium level damage, D - high-level damage, and E
- total damage
chemotherapy combinations, to potentiate the effects of
agents with similar effects. Dexamethasone, a medicine
that induces DNA strand breaks and depletion of NAD
pools against steroid-sensitive mouse lymphoma cells was
potentiated by TR (29). The same team previously found
that TR interferes with the synthesis of NAD, reduces the
cellular content of NAD, and serves as a weak inhibitor of
poly (ADP-ribose) polymerase, an enzyme that requires
NAD for normal DNA repair processes (23).
In summary, a genotoxic effect related to exposure to
TR in WBC was revealed using the comet assay, one of the
most accepted assays used to detect DNA damage. Our
investigation of the TR-treated cells and relationship to the
formation of DNA damage demonstrates the dose-
dependent DNA damage induced by TR, with lower-grade
damage being more present in affected cells.
ACKNOwleDgmeNTs
This research was supported by the Ministry of
Education, Science and Technological Development of
Serbia (No. 451-03-68/2020-14/200161) and hCOMET
COST action (No. 15132).
RefeReNCes
1. Ratcliffe AJ. Inosine 5'-monophosphate
dehydrogenase inhibitors for the treatment of
autoimmune diseases. Curr Opin Drug Discov Devel
2006; 9: 595-605.
2. Hedstrom L, Liechti G, Goldberg JB, Gollapalli DR.
The antibiotic potential of prokaryotic IMP
dehydrogenase inhibitors. Curr Med Chem 2011; 18:
1909-18. 
3. Juvale K, Shaik A, Kirubakaran S. Inhibitors of inosine
5′-monophosphate dehydrogenase as emerging new
generation antimicrobial agents. Med Chem Commun
2019; 10: 1290-301.
4. Hedstrom L. IMP dehydrogenase: structure,
mechanism and inhibition. Chem Rev 2009; 109:
2903–28.
5. Allison AC, Eugui EM. Mycophenolate mofetil and its
mechanisms of action. Immunopharmacology 2000;
47: 85-118.
6. Chong CR, Qian DZ, Pan F, et al. Identification of type
I inosine monophosphate dehydrogenase as an
antiangiogenic drug target. J Med Chem 2006; 49:
2677-80.
7. Kojić V, Spaić S, Svirčev M, et al. 2-Substituted
thiazole-4-carboxamide derivatives as tiazofurin
mimics: synthesis and in vitro antitumour activity.
Tetrahedron 2014; 70: 2343-50.
8. Malek K, Boosalis MS, Waraska K, Mitchell BS,
Wright DG. Effects of the IMP-dehydrogenase
inhibitor, Tiazofurin, in bcr-abl positive acute
myelogenous leukemia. Part I. In vivo studies. Leuk
Res 2004; 28: 1125-36.
9. Naffouje R, Grover P, Yu H, et al. Anti-tumor potential
of IMP dehydrogenase inhibitors: a century-long story.
Cancers 2019; 11: 1346.
10. Weber G, Yamaji Y, Olah E, et al. Clinical and
molecular impact of inhibition of IMP dehydrogenase
activity by tiazofurin. Adv Enzyme Regul 1989; 28:
335-56.
11. Braun-Sand SB, Peetz M. Inosine monophosphate
dehydrogenase as a target for antiviral, anticancer,
antimicrobial and immunosuppressive therapeutics.
Future Med Chem 2010; 2: 81–92.
12. Savic D, Lavrnja I, Dacic S, et al. Tiazofurin
modulates lipopolysaccharide-activated microglia in
vitro. Arch Biol Sci 2014; 66: 1633-40.
13. Kusumanchi P, Zhang Y, Jani M, et al. Nicotinamide
mononucleotide adenylyltransferase 2 overexpression
enhances colorectal cancer cell-kill by tiazofurin.
Cancer Gene Ther 2013; 20: 403–12.
14. Popsavin M, Torović L, Svircev M, et al. Synthesis and
antiproliferative activity of two new tiazofurin analogs
with 2'-amido functionalities. Bioorg Med Chem Lett
2006; 16: 2773–6.
15. Sayed AR, Gomha SM, Abdelrazek FM, Farghaly MS,
Hassan SA, Metz P. Design, efficient synthesis and
molecular docking of some novel thiazolyl-pyrazole
derivatives as anticancer agents. BMC Chemistry
2019; 13: 116.
16. Vitale M, Zamai L, Falcieri E, et al. IMP
dehydrogenase inhibitor, tiazofurin, induces apoptosis
in K562 human erythroleukemia cells. Cytometry
1997; 30: 61-6.
17. Mariani AR, Columbaro M, Zauli G, et al. Lineage-
related susceptibility of human hemopoietic cell lines
to apoptosis. Anat Rec 1999; 254: 1–6.
18. Grifantini M. ICN tiazofurin, pharmaceuticals. Curr
Opin Invesig Drugs 2001; 1: 257-62.
19. Wright DG, Boosalis MS, Waraska K, Oshry LJ,
Weintraub LR, Vosburgh E. Tiazofurin effects on IMP-
dehydrogenase activity and expression in the leukemia
cells of patients with CML blast crisis. Anticancer Res
1996; 16: 3349-51.
20. Grem JL, Rubinstein L, King SA, et al. Clinical
toxicity associated with tiazofurin. Investig New
Drugs 1990; 8: 227–38.
94
doi: 10.5937/mckg54-28798
COBISS . SR - ID 32964105
UDK. 615.277.065 Med. čas. 2020; 54(3): 91-95.
21. Joksic G, Stankovic M, Radovanovic S, Dragic M. The
use of cytochalasin block (CB) micronucleus test to
identify clastogenic and antiproliferative action of
tiazofurin. Arch Oncol 2001; 9: 47-8.
22. Kojić V, Popsavin M, Spaić S, et al. Structure based
design, synthesis and in vitro antitumor activity of
tiazofurin stereoisomers with nitrogen functions at the
C-2′ or C-3′ positions. Eur J Med Chem 2019; 183:
111712.
23. Berger NA, Berger SJ, Catino DM, et al. Modulation
of nicotin-amide adenin dinucleotid and
poly(adenosine diphosphoribose) metabolism by the
sythex “C” nucleoside analogs, tiazofurin and
selenazofurin. J Clin Invest 1985; 75: 702-9.
24. Tang X, Zhao A, Hong Y. Tiazofurin inhibits oral
cancer growth in vitro and in vivo via upregulation of
miR-204 expression. Trop J Pharm Res 2020; 19:
1377-82.
25. Finlay GJ, Ching LM, Wilson WR, Baguley BC.
Resistance of cultured Lewis lung carcinoma cell lines
to tiazofurin. J Natl Cancer Inst 1987; 79: 291-6.
26. Singh NP, McCoy MT, Tice RR, et al. A simple
technique for quantitation of low levels of DNA
damage in individual cells. Exp Cell Res 1998; 175:
184–91.
27. Anderson D, Yu TW, Phillips BJ, et al. The effect of
various antioxidants and other modifying agents on
oxygen-radical-generated DNA damage in human
lymphocytes in the comet assay. Mutat Res 1994; 307:
261–71.
28. Tóvári J, Bocsi J, Ladányi A, Lapis K, Timár J. The
antitumor effect of tiazofurin (TR) consists of anti-
proliferative and anti-invasive elements. Anticancer
Research 1996; 16: 3307-12.
29. Berger NA, Berger SJ, Sudar DC et al. Role of
nicotinamide adenine dinucleotide and adenosine
triphosphate in glucocorticoid-induced cytotoxicity




COBISS . SR - ID 32964105
UDK. 615.277.065 Med. čas. 2020; 54(3): 91-95.
